The FDA has approved several landmark neurological drugs in 2024–2025 that mark meaningful advances in brain disease treatment. Kisunla (donanemab) became the second amyloid-targeting therapy approved for Alzheimer's disease in 2024, offering a potential disease-modifying option for early-stage patients. Crexont introduced an extended-release formulation of carbidopa/levodopa for more consistent Parkinson's symptom control. IMAVI (nipocalimab) broke new ground in myasthenia gravis by blocking the FcRn receptor, making it effective for both AChR- and MuSK-positive patients aged 12 and older. Adsumi brought a new nasal powder delivery of dihydroergotamine for acute migraine relief. Together, these approvals reflect accelerating momentum in neurology drug development, offering clinicians and patients new tools across a spectrum of debilitating conditions.
